CLAIM CARD
Despite these positive mechanistic signals, the evidence base for immune-related longevity outcomes remains limited and contextual. The reviewed findings are derived from secondary endpoint analyses in trials not primarily designed to assess longevity, and the clinical significance of the magnitude of biomarker change is not established (Gomaz 2025). Furthermore, the broader synthesis indicates that positive signals for ARBs in longevity are often context-dependent and may not translate to hard clinical endpoints like mortality, highlighting the tension between biomarker improvement and definitive survival benefit.
Evidence grade: exploratory
Contradiction status: none
Publication: edeb045d-18ed-49dc-95b6-57f76783ce2b
Provenance: Derivation Web chain
Citation Support
source_1Solomon 2026source_2Din 2026source_3Li 2025source_4Mei 2025source_5Chung 2024